JACK BENDHEIM - 21 Jan 2026 Form 4 Insider Report for PHIBRO ANIMAL HEALTH CORP (PAHC)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim
Issuer symbol
PAHC
Transactions as of
21 Jan 2026
Net transactions value
-$1,164,547
Form type
4
Filing time
22 Jan 2026, 19:41:32 UTC
Previous filing
15 Jan 2026
Next filing
27 Jan 2026
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
BENDHEIM JACK President and CEO, Director, 10%+ Owner 300 FRANK W. BURR BLVD., STE 21, TEANECK /s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim 22 Jan 2026 0001241560
BFI Co., LLC 10%+ Owner 300 FRANK W. BURR BLVD., STE 21, TEANECK /s/ Judith Weinstein, as Attorney-in-Fact for BFI Co., LLC 22 Jan 2026 0001601607

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PAHC Class A Common Stock Sale $612,128 -14,687 -33% $41.68 29,838 21 Jan 2026 See F1, F2, F3
transaction PAHC Class A Common Stock Sale $497,665 -11,875 -100% $41.91 18 22 Jan 2026 See F1, F3, F4
transaction PAHC Class A Common Stock Sale $54,755 -1,283 -7.1% $42.68 16,680 22 Jan 2026 See F1, F3, F5
holding PAHC Class A Common Stock 16,840 21 Jan 2026 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.11 to $42.02. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.
F3 The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $42.53.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.62 to $42.77.
F6 The reported securities are directly held by Jack Bendheim.